DOI QR코드

DOI QR Code

The Pharmacokinetics of Nimodipine After Oral Administration in Rabbits with Hepatic Failure

  • Published : 2006.02.20

Abstract

The pharmacokinetics of nimodipine, following a single 16 mg/kg oral dose, was investigated in rabbits with hepatic failure induced by 0.5 mL/kg (mild), 1.0 mL/kg (moderate) and 2.0 mL/kg (severe) of carbon tetrachloride $(CCl_{4}$ : olive oil = 20 : 80, v/v). The plasma concentrations of nimodipine were determined by a high performance liquid chromatographic assay. The levels of sGOT and sGPT in rabbits with mild $(86.2{\pm}29.0\;and\;98.5{\pm}33.1\;unit/dL)$, moderate $(168.1{\pm}61.2\;and\;196.2{\pm}66.0\;unit/dL)$ and severe $(292.7{\pm}82.2\;and\;314.2{\pm}99.8\;unit/dL)$ hepatic failure were significantly increased compared to the control $(38.0{\pm}10.1\;and\;32.4{\pm}10.2\;unit/dL)$. The area under the plasma concentration-time curve (AUC) of nimodipine was significantly increased in mild $(131.7{\pm}28.1%)$, moderate $(168.8{\pm}32.8%)$ and severe $(204.6{\pm}58.3%)$ carbon tetrachloride-induced hepatic failure rabbits compared to the control (100%) rabbits. The volume of distribution $(V_{d})$ and the total body clearance $(CL_{t})$ of nimodipine were significantly decreased in all hepatic failure groups. The elimination rate constant $(K_{el})$ of nimodipine was significantly decreased in moderate and severe carbon tetrachloride-induced hepatic failure rabbits. There was a correlation between sGOT (y= 1.01x+241, r=0.993) or sGPT (y=0.92x +243, r=0.997) value and the AUC of nimodipine in the rabbits with hepatic failure. These findings suggest that the hepatic metabolism of nimodipine was inhibited by carbon tetrachloride-induced hepatic failure rabbits, resulting in the decrese in $V_{d}$ and $CL_{t}$ of nimodipine in the rabbits with mild, moderate and severe hepatic failure.

Keywords

References

  1. S. Kazda, B. Garthoff, H.P. Krause and K. Schlossmann, Cerebrovascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments, Arzneimittelforschung., 32, 331-338 (1982)
  2. H. Scholz, Pharmacological aspects of calcium channel blockers, Cardiovasc. Drugs Ther., 10, 869-872 (1997) https://doi.org/10.1007/BF00051613
  3. M. Epstein and R.D. Loutzenhister, Effects of calcium antagonists on renal hemodynamics, Am. J. Kidney Dis., 16, 10-14 (1990)
  4. D. Maruhn, H.M. Siefert, H. Weber, K. Ramsch and D. Suwelack, Pharmacokinetics of nimodipine. I. communication: absorption, concentration in plasma and excretion after single administration of [$^{14}C$] nimodipine in rat, dog and monkey, Arzneimittelforschung., 35, 1781-1786 (1985)
  5. D. Suwelack, H. Weber and D. Maruhn, Pharmacokinetics of nimodipine, II. communication: absorption, concentration in plasma and excretion after single administration of [$^{14}C$]nimodipine in rat, dog and monkey, Arzneimittelforschung., 35, 1787-1794 (1985)
  6. K.D. Ramsch, G Ahr, D. Tettenborn and L.M. Auer, Overview on pharmacokinetics of nimodipine in healthy volunteer and in patients with subarachnoid hemorrhage, Neurochirurgia., 28, 74-78 (1985)
  7. D. Scherling, K. Buhner, H.P. Krause, W Karl and C. Wunsche, Biotransformation of nimodipine in rat, dog and monkey, Arzneimittelforschung., 41, 392-398 (1991)
  8. F.P. Guengerich, W.R. Brian, M. Iwasaki, M.A. Sari, C. Baarnhielm and P. Berntssom, Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrom P-450IIIA4, J. Med. Chem., 34,1834-1844 (1991)
  9. M. Qian and J.M. Gallo, High-perfomance liquod chromatographic determinination of the calcium channel blocker nimodipine in monkey plasma, J. Chromatogr., 578, 316-320 (1992) https://doi.org/10.1016/0378-4347(92)80432-P
  10. M.L. Rocci and WJ. Jusko, LAGRAN program for area and moments in pharmacokinetic analysis, Computer Programs in Biomedicine, 16, 203-209 (1983) https://doi.org/10.1016/0010-468X(83)90082-X
  11. J. Lobo, D.B. Jack and MJ. Kendall, Inter- and intra- subjects variability of nitrendipine and the effects of food, Eur. J. Clin. Pharmacol., 32, 357-360 (1987) https://doi.org/10.1007/BF00543969
  12. R. Laplanche, B. Fertil, E. Niiesch and J.L. Steimer, Exploratory analysis population pharmacokinetic data from clinical trials with application to isradipine, Clin. Pharmacol. Ther., 50, 39-54 (1991) https://doi.org/10.1038/clpt.1991.102
  13. J.G Kelly and K. O'Malley, Clinical pharmacokinetics of calcium antagonists, Clin. Pharmacokinet., 22, 416-433 (1992) https://doi.org/10.2165/00003088-199222060-00002
  14. B.G Woodcock, I. Rietbrock, H.F. Vohringer and N. Rietbrock, Verapamil disposition in liver disease and intensive-care patients: Kinetics, clearance, and apparent blood flow relationships, Clin. Pharmacol. Ther., 29, 27-34 (1981) https://doi.org/10.1038/clpt.1981.5
  15. A. Somogyi, M. Albrecht, G Kliems, K. Schafer and M. Eichelbaum, Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis, Brit. J. Clin. Pharmacol., 12, 51-60 (1981) https://doi.org/10.1111/j.1365-2125.1981.tb01854.x